Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Iksuda Therapeutics
Iksuda Therapeutics
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
OINDPs: Nosey about recent developments?
OINDPs are a user friendly and efficacious alternative to injectables in several disease areas
Transforming healthcare with patient centricity
In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact...
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Compact process thermostat for efficient temperature control in the laboratory
The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
AviadoBio expands presence at Canary Wharf
The company has acquired 11,000 sqft of laboratory and office space in Canary Wharf to accommodate the growing team
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Research & Development
LegoChem and Iksuda expand ADC license agreement
In April 2020, Iksuda licensed global development and commercialisation rights for three ADC programmes using LCB's ADC linker/toxin platform
Finance
ADC developer Iksuda Therapeutics closes $47m financing round
The company’s lead preclinical candidate, IKS03, is a CD19-targeted ADC candidate for B-cell cancers
Research & Development
Iksuda releases first data on ADC efficacy on tumour regression
British next-gen Antibody Drug Conjugates developer says its IKS01 allows for the targeted delivery of a potent cytotoxic payload to tumours
Pharmaceutical
Iksuda and Femtogenix ink solid tumour agreement
Iksuda has stated it will use Femtogenix payload molecules to progress its lead antibody drug conjugate
Media
Glythera announces corporate name change and rebranding
Now the primary focus of Iksuda Therapeutics will be on the development of superior ADCs for treatment of difficult-to-treat cancers
Ingredients
Glythera appoints Professor Kerry Chester to SAB
Recruitment
Glythera appoints Chief Scientific Officer and strengthens SAB
Subscribe now